

Kia ora and welcome to our August newsletter,

We are so excited to be able to share with you our latest clinical trial. The New Zealand Brain Research Institute is becoming a centre in the massive international Skyline trial by Roche. This aims to identify people who are at elevated risk of Alzheimer's and test a novel antibody that could actually prevent the disease from taking hold. For both Parkinson's and Alzheimer's, by the time people are diagnosed, a lot of irreversible damage has already occurred. For effective treatments or cures, we really need to begin that treatment before noticeable symptoms begin. After years of careful research, we are now in the position of being able to identify people who are in that 'Goldilocks' zone. This is an exciting period for clinical research, with reasonable hope that there may soon be effective options to prevent the onset of what are currently incurable diseases. Read below for details on who is eligible for this study.

Here at the New Zealand Brain Research Institute we don't receive direct government funding but are dependent on grants, donations and bequests. Our research is limited by funding and we need your support to continue this work. We hope to see you at our biggest fundraiser of the year, Music Meets Art, for a fabulous evening supporting brain research in Canterbury.

# Raising funds for neurological research in Canterbury

Come join us at our biggest fundraiser of the year with a fabulous night of popular opera and musical theatre. You will be supporting research right here in Canterbury, helping patients and families suffering the devastating effects of neurological conditions such as Alzheimer's and Parkinson's disease, dementia and MS, amongst many others.

Tickets are \$79 and include Pegasus Bay wine, sumptuous canapés, entertainment and a chance to own a beautiful piece of art. You can even meet our researchers!

## **MUSIC MEETS ART**

### Saturday 13th August 7pm at "THE PIANO", 156 Armagh St, Christchurch

#### Purchase tickets for Music Meets Art here



## We are now recruiting for Alzheimer's Dementia Clinical Trial

We are now recruiting for the worldwide clinical trial of a new investigational treatment (gantenerumab) for people who are at risk for Alzheimer's Dementia.

Alzheimer's dementia is thought to be caused by a combination of factors which trigger brain changes, with the subsequent accumulation of amyloid protein outside the brain cells (neurones) and tau protein tangles inside brain cells. This ultimately leads to loss of brain cells and symptoms. Research shows that amyloid accumulation may start up to 20 years prior the start of clinical symptoms. This study is therefore looking at the effect of gantenerumab on people with normal cognition, but who are at risk of developing Alzheimer's dementia because they have increased level of amyloid in their brain.

To be eligible for this study, participants have to be 60-80 years old, have normal cognition and have elevated level of amyloid protein in the brain; which can be evaluated by screening. To enquire about being part of the trial, please call 0800 114 903 or email <u>trials@nzbri.org</u>



For more information about our work or how to support us, contact us at: Website: <u>www.nzbri.org</u> Or email: <u>info@nzbri.org</u>

Join us on <u>Facebook</u> for up-to-date NZBRI research as well as staff profiles and NZBRI events.

Stay safe Ngā mihi

The New Zealand Brain Research Institute Team





Copyright © 2021 New Zealand Brain Research Institute, All rights reserved. info@nzbri.org